

1-1 By: Janek S.B. No. 943  
1-2 (In the Senate - Filed February 27, 2007; March 7, 2007,  
1-3 read first time and referred to Committee on Health and Human  
1-4 Services; April 2, 2007, reported adversely, with favorable  
1-5 Committee Substitute by the following vote: Yeas 9, Nays 0;  
1-6 April 2, 2007, sent to printer.)

1-7 COMMITTEE SUBSTITUTE FOR S.B. No. 943 By: Janek

1-8 A BILL TO BE ENTITLED  
1-9 AN ACT

1-10 relating to the licensing and regulation of wholesale distributors  
1-11 of prescription drugs; providing penalties.

1-12 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS:

1-13 SECTION 1. Section 431.401, Health and Safety Code, is  
1-14 amended by amending Subdivisions (5) and (11) and adding  
1-15 Subdivisions (3-a), (3-b), (4-a), (4-b), (10-a), and (12) to read  
1-16 as follows:

1-17 (3-a) "Co-licensed product partner" means one of two  
1-18 or more parties that have the right to engage in the manufacturing  
1-19 or marketing of a prescription drug consistent with the United  
1-20 States Food and Drug Administration's regulations and guidances  
1-21 implementing the Prescription Drug Marketing Act of 1987 (Pub. L.  
1-22 No. 100-293).

1-23 (3-b) "Drop shipment" means the sale of a prescription  
1-24 drug to a wholesale distributor by the manufacturer of the  
1-25 prescription drug, or by the manufacturer's co-licensed product  
1-26 partner, third-party logistics provider, or exclusive distributor,  
1-27 in which:

1-28 (A) the wholesale distributor takes title but not  
1-29 physical possession of the prescription drug;

1-30 (B) the wholesale distributor invoices the  
1-31 pharmacy, chain pharmacy warehouse, or other person authorized by  
1-32 law to dispense or administer the drug to a patient; and

1-33 (C) the pharmacy, chain pharmacy warehouse, or  
1-34 other authorized person receives delivery of the prescription drug  
1-35 directly from the manufacturer or the manufacturer's third-party  
1-36 logistics provider or exclusive distributor.

1-37 (4-a) "Manufacturer" means a person licensed or  
1-38 approved by the United States Food and Drug Administration to  
1-39 engage in the manufacture of drugs or devices, consistent with the  
1-40 federal agency's definition of "manufacturer" under the agency's  
1-41 regulations and guidances implementing the Prescription Drug  
1-42 Marketing Act of 1987 (Pub. L. No. 100-293).

1-43 (4-b) "Manufacturer's exclusive distributor" means a  
1-44 person who holds a wholesale distributor license under this  
1-45 subchapter, who contracts with a manufacturer to provide or  
1-46 coordinate warehousing, distribution, or other services on behalf  
1-47 of the manufacturer, and who takes title to, but does not have  
1-48 general responsibility to direct the sale or disposition of, the  
1-49 manufacturer's prescription drug. A manufacturer's exclusive  
1-50 distributor must be an authorized distributor of record to be  
1-51 considered part of the normal distribution channel.

1-52 (5) "Normal distribution channel [~~chain~~]" means a  
1-53 chain of custody for a prescription drug, either directly or by drop  
1-54 shipment, from the manufacturer of the prescription drug, the  
1-55 manufacturer to the manufacturer's co-licensed product partner,  
1-56 the manufacturer to the manufacturer's third-party logistics  
1-57 provider, or the manufacturer to the manufacturer's exclusive  
1-58 distributor, to:

1-59 (A) [~~a manufacturer to an authorized distributor~~  
1-60 ~~of record or to a wholesale distributor licensed under this~~  
1-61 ~~subchapter to] a pharmacy to:~~

1-62 (i) a patient; or  
1-63 (ii) another designated person authorized

2-1 by law to dispense or administer the drug [~~practitioner~~] to a  
 2-2 patient;  
 2-3 (B) a wholesale distributor to:  
 2-4 (i) a pharmacy to a patient; or  
 2-5 (ii) another designated person authorized  
 2-6 by law to dispense or administer the drug [~~a manufacturer to an~~  
 2-7 authorized distributor of record to one other authorized  
 2-8 distributor of record to a pharmacy or practitioner] to a patient;  
 2-9 [~~or~~]  
 2-10 (C) a wholesale distributor [~~a manufacturer to~~  
 2-11 an authorized distributor of record] to a chain pharmacy warehouse  
 2-12 to the chain pharmacy warehouse's intracompany pharmacy or other  
 2-13 designated person authorized by law to dispense or administer the  
 2-14 drug [~~a pharmacy or practitioner~~] to a patient; or  
 2-15 (D) an authorized prescriber of a drug that, by  
 2-16 law, may be administered only under the supervision of the  
 2-17 prescriber.  
 2-18 (10-a) "Third-party logistics provider" means a  
 2-19 person who holds a wholesale distributor license under this  
 2-20 subchapter, who contracts with a prescription drug manufacturer to  
 2-21 provide or coordinate warehousing, distribution, or other services  
 2-22 on behalf of the manufacturer, and who does not take title to the  
 2-23 prescription drug or have general responsibility to direct the  
 2-24 prescription drug's sale or disposition. A third-party logistics  
 2-25 provider must be an authorized distributor of record to be  
 2-26 considered part of the normal distribution channel.  
 2-27 (11) "Wholesale distribution" means distribution of  
 2-28 prescription drugs to a person other than a consumer or patient[~~7~~  
 2-29 and includes distribution by a manufacturer, repackager, own label  
 2-30 distributor, broker, jobber, warehouse, retail pharmacy that  
 2-31 conducts wholesale distribution, or wholesaler]. The term does not  
 2-32 include:  
 2-33 (A) intracompany sales of prescription drugs,  
 2-34 which means transactions or transfers of prescription drugs between  
 2-35 a division, subsidiary, parent, or affiliated or related company  
 2-36 that is under common ownership and control of a corporate entity, or  
 2-37 any transaction or transfer between co-license holders of a  
 2-38 co-licensed product;  
 2-39 (B) the sale, purchase, distribution, trade, or  
 2-40 transfer of prescription drugs or the offer to sell, purchase,  
 2-41 distribute, trade, or transfer a prescription drug for emergency  
 2-42 medical reasons;  
 2-43 (C) the distribution of prescription drug  
 2-44 samples by a representative of a manufacturer;  
 2-45 (D) the return of drugs by a hospital, health  
 2-46 care entity, [~~retail pharmacy, chain pharmacy warehouse,~~]  
 2-47 or charitable institution in accordance with 21 C.F.R. Section 203.23;  
 2-48 [~~or~~]  
 2-49 (E) the sale of reasonable quantities [~~delivery~~]  
 2-50 by a retail pharmacy of a prescription drug to [~~a patient or a~~  
 2-51 patient's agent under the lawful order of] a licensed practitioner  
 2-52 for office use;  
 2-53 (F) the sale, purchase, or trade of a drug, an  
 2-54 offer to sell, purchase, or trade a drug, or the dispensing of a  
 2-55 drug under a prescription;  
 2-56 (G) the sale, transfer, merger, or consolidation  
 2-57 of all or part of the business of a pharmacy from or with another  
 2-58 pharmacy, whether accomplished as a purchase and sale of stock or  
 2-59 business assets;  
 2-60 (H) the sale, purchase, distribution, trade, or  
 2-61 transfer of a prescription drug from one authorized distributor of  
 2-62 record to one additional authorized distributor of record if:  
 2-63 (i) the manufacturer states in writing to  
 2-64 the receiving distributor that the manufacturer is unable to supply  
 2-65 the prescription drug; and  
 2-66 (ii) the supplying distributor states in  
 2-67 writing that the prescription drug being supplied had until that  
 2-68 time been exclusively in the normal distribution channel;  
 2-69 (I) the delivery of, or offer to deliver, a

3-1 prescription drug by a common carrier solely in the common  
 3-2 carrier's usual course of business of transporting prescription  
 3-3 drugs, if the common carrier does not store, warehouse, or take  
 3-4 legal ownership of the prescription drug; or

3-5 (J) the sale or transfer from a retail pharmacy  
 3-6 or chain pharmacy warehouse of expired, damaged, returned, or  
 3-7 recalled prescription drugs to the original manufacturer or to a  
 3-8 third-party returns processor.

3-9 (12) "Wholesale distributor" means a person engaged in  
 3-10 the wholesale distribution of prescription drugs, including a  
 3-11 manufacturer, repackager, own-label distributor, private-label  
 3-12 distributor, jobber, broker, manufacturer warehouse, distributor  
 3-13 warehouse, or other warehouse, manufacturer's exclusive  
 3-14 distributor, authorized distributor of record, drug wholesaler or  
 3-15 distributor, independent wholesale drug trader, specialty  
 3-16 wholesale distributor, third-party logistics provider, retail  
 3-17 pharmacy that conducts wholesale distribution, and chain pharmacy  
 3-18 warehouse that conducts wholesale distribution. A wholesale  
 3-19 distributor must be an authorized distributor of record to be  
 3-20 considered part of the normal distribution channel.

3-21 SECTION 2. Section 431.4031, Health and Safety Code, is  
 3-22 amended to read as follows:

3-23 Sec. 431.4031. EXEMPTION FROM CERTAIN PROVISIONS FOR  
 3-24 CERTAIN WHOLESAL DISTRIBUTORS. A wholesale distributor that  
 3-25 distributes prescription drugs that are medical gases or a  
 3-26 wholesale distributor that is a manufacturer or a third-party  
 3-27 logistics provider on behalf of a manufacturer is exempt from  
 3-28 Sections 431.404(a)(5) and (6), (b), [431.404(b)] and (c),  
 3-29 431.4045, 431.405, 431.407, and 431.408[, 431.412, and 431.413].

3-30 SECTION 3. Subsections (a), (b), and (d), Section 431.404,  
 3-31 Health and Safety Code, are amended to read as follows:

3-32 (a) An applicant for a license under this subchapter must  
 3-33 submit an application to the department on the form prescribed by  
 3-34 the department. The application must contain:

3-35 (1) the name, full business address, and telephone  
 3-36 number of the applicant;

3-37 (2) all trade or business names under which the  
 3-38 business is conducted;

3-39 (3) [~~(2)~~] the address, [~~and~~] telephone number, and  
 3-40 name of a contact person for each of the applicant's places of  
 3-41 business [~~of each place of business that is licensed~~];

3-42 (4) [~~(3)~~] the type of business entity and:

3-43 (A) if the business is a sole proprietorship, the  
 3-44 name of the proprietor;

3-45 (B) if the business is a partnership, the name of  
 3-46 the partnership and each of the partners; or

3-47 (C) if the business is a corporation, the name of  
 3-48 the corporation, the place of incorporation, and the name and title  
 3-49 of each corporate officer and director [~~the name and residence~~  
 3-50 address of:

3-51 [~~(A) the proprietor, if the business is a~~  
 3-52 proprietorship,

3-53 [~~(B) all partners, if the business is a~~  
 3-54 partnership, or

3-55 [~~(C) all principals, if the business is an~~  
 3-56 association];

3-57 [~~(4) the date and place of incorporation, if the~~  
 3-58 business is a corporation,]

3-59 (5) [~~the names and business addresses of the~~  
 3-60 individuals in an administrative capacity showing:

3-61 [~~(A) the managing proprietor, if the business is~~  
 3-62 a proprietorship,

3-63 [~~(B) the managing partner, if the business is a~~  
 3-64 partnership,

3-65 [~~(C) the officers and directors, if the business~~  
 3-66 is a corporation, or

3-67 [~~(D) the persons in a managerial capacity, if the~~  
 3-68 business is an association,

3-69 [~~(6)~~] the name and [~~7~~] telephone number of, and any

4-1 information necessary to complete a criminal history record check  
4-2 on, a designated representative of each place of business; and  
4-3 (6) [~~(7) the state of incorporation, if the business~~  
4-4 ~~is a corporation,~~

4-5 [~~(8)~~] a list of all licenses and permits issued to the  
4-6 applicant by any other state under which the applicant is permitted  
4-7 to purchase or possess prescription drugs[, and

4-8 [~~(9) the name of the manager for each place of~~  
4-9 ~~business].~~

4-10 (b) Each person listed in Subsection (a)(5) [~~Subsections~~  
4-11 ~~(a)(6) and (a)(9)~~] shall provide the following to the department:

4-12 (1) the person's places of residence for the past seven  
4-13 years;

4-14 (2) the person's date and place of birth;

4-15 (3) the person's occupations, positions of employment,  
4-16 and offices held during the past seven years;

4-17 (4) the business name and address of any business,  
4-18 corporation, or other organization in which the person held an  
4-19 office under Subdivision (3) or in which the person conducted an  
4-20 occupation or held a position of employment;

4-21 (5) a statement of whether during the preceding seven  
4-22 years the person was the subject of a proceeding to revoke a license  
4-23 or a criminal proceeding and the nature and disposition of the  
4-24 proceeding;

4-25 (6) a statement of whether during the preceding seven  
4-26 years the person has been enjoined, either temporarily or  
4-27 permanently, by a court from violating any federal or state law  
4-28 regulating the possession, control, or distribution of  
4-29 prescription drugs, including the details concerning the event;

4-30 (7) a written description of any involvement by the  
4-31 person as an officer or director with any business, including any  
4-32 investments, other than the ownership of stock in a publicly traded  
4-33 company or mutual fund during the past seven years, that  
4-34 manufactured, administered, prescribed, distributed, or stored  
4-35 pharmaceutical products and any lawsuits in which the businesses  
4-36 were named as a party;

4-37 (8) a description of any misdemeanor or felony offense  
4-38 for which the person, as an adult, was found guilty, regardless of  
4-39 whether adjudication of guilt was withheld or whether the person  
4-40 pled guilty or nolo contendere;

4-41 (9) a description of any criminal conviction of the  
4-42 person under appeal, a copy of the notice of appeal for that  
4-43 criminal offense, and a copy of the final written order of an appeal  
4-44 not later than the 15th day after the date of the appeal's  
4-45 disposition; and

4-46 (10) a photograph of the person taken not earlier than  
4-47 30 days before the date the application was submitted.

4-48 (d) An applicant or license holder shall submit to [~~file~~  
4-49 ~~with]~~ the department [~~a written notice of~~] any change in or  
4-50 correction to the information required under this section in the  
4-51 form and manner prescribed by the department.

4-52 SECTION 4. Subchapter N, Chapter 431, Health and Safety  
4-53 Code, is amended by adding Section 431.4045 to read as follows:

4-54 Sec. 431.4045. INSPECTION REQUIRED. The department may not  
4-55 issue a wholesale distributor license to an applicant under this  
4-56 subchapter unless the department:

4-57 (1) conducts a physical inspection of the place of  
4-58 business at the address provided by the applicant under Section  
4-59 431.404; and

4-60 (2) determines that the designated representative of  
4-61 the place of business meets the qualifications required by Section  
4-62 431.405.

4-63 SECTION 5. Section 431.405, Health and Safety Code, is  
4-64 amended to read as follows:

4-65 Sec. 431.405. QUALIFICATIONS FOR LICENSE. To qualify for  
4-66 the issuance or renewal of a wholesale distributor license under  
4-67 this subchapter, the designated representative of an applicant or  
4-68 license holder must:

4-69 (1) be at least 21 years of age;

5-1 (2) have been employed full-time for at least three  
5-2 years by a pharmacy or a wholesale distributor in a capacity related  
5-3 to the dispensing or distributing of prescription drugs, including  
5-4 recordkeeping for the dispensing or distributing of prescription  
5-5 drugs;

5-6 (3) be employed by the applicant full-time in a  
5-7 managerial-level position;

5-8 (4) be actively involved in and aware of the actual  
5-9 daily operation of the wholesale distributor;

5-10 (5) be physically present at the applicant's place of  
5-11 business during regular business hours, except when the absence of  
5-12 the designated representative is authorized, including sick leave  
5-13 and vacation leave;

5-14 (6) serve as a designated representative for only one  
5-15 applicant at any one time, except in a circumstance in which more  
5-16 than one licensed wholesale distributor is colocated in the same  
5-17 place of business and the wholesale distributors are members of an  
5-18 affiliated group, as defined by Section 1504, Internal Revenue Code  
5-19 of 1986;

5-20 (7) not have been convicted of a violation of any  
5-21 federal, state, or local laws relating to wholesale or retail  
5-22 prescription drug distribution or the distribution of controlled  
5-23 substances; and

5-24 (8) not have been convicted of a felony under a  
5-25 federal, state, or local law.

5-26 SECTION 6. Section 431.408, Health and Safety Code, is  
5-27 amended by adding Subsections (a-1) and (c-1) to read as follows:

5-28 (a-1) A chain pharmacy warehouse that engages only in  
5-29 intracompany transfers is exempt from the bond requirement under  
5-30 Subsection (a).

5-31 (c-1) A single bond is sufficient to cover all places of  
5-32 business operated by a wholesale distributor in this state.

5-33 SECTION 7. Subchapter N, Chapter 431, Health and Safety  
5-34 Code, is amended by adding Section 431.4095 to read as follows:

5-35 Sec. 431.4095. RENEWAL NOTIFICATION; CHANGE OR RENEWAL.

5-36 (a) Before the expiration of a license issued under this  
5-37 subchapter, the department shall send to each licensed wholesale  
5-38 distributor a form containing a copy of the information the  
5-39 distributor provided to the department under Section 431.404.

5-40 (b) Not later than the 30th day after the date the wholesale  
5-41 distributor receives the form under Subsection (a), the wholesale  
5-42 distributor shall identify and state under oath to the department  
5-43 any change in or correction to the information.

5-44 SECTION 8. Subchapter N, Chapter 431, Health and Safety  
5-45 Code, is amended by adding Sections 431.4101 and 431.4102 to read as  
5-46 follows:

5-47 Sec. 431.4101. CONTINUING EDUCATION. Designated  
5-48 representatives identified in Section 431.404(a)(5) shall  
5-49 successfully complete continuing education training regarding  
5-50 applicable federal and state laws governing the wholesale  
5-51 distribution of prescription drugs as required by department rule.

5-52 Sec. 431.4102. CONFIDENTIALITY. Information provided  
5-53 under Section 431.404 may not be disclosed to any person other than  
5-54 the department for licensing or monitoring purposes.

5-55 SECTION 9. Section 431.411, Health and Safety Code, is  
5-56 amended by amending Subsection (a) and adding Subsections (a-1) and  
5-57 (e) to read as follows:

5-58 (a) A wholesale distributor shall receive prescription drug  
5-59 returns or exchanges from a pharmacy or chain pharmacy warehouse in  
5-60 accordance with the terms and conditions of the agreement between  
5-61 the wholesale distributor and the pharmacy or chain pharmacy  
5-62 warehouse. An expired, damaged, recalled, or otherwise nonsalable  
5-63 prescription drug that is returned to the wholesale distributor may  
5-64 be distributed by the wholesale distributor only to either the  
5-65 original manufacturer or a third-party returns processor. The  
5-66 returns or exchanges, salable or otherwise, received by the  
5-67 wholesale distributor as provided by this subsection, including any  
5-68 redistribution of returns or exchanges by the wholesale  
5-69 distributor, are not subject to the pedigree requirement under

6-1 Section 431.412 if the returns or exchanges are exempt from  
 6-2 pedigree under:

6-3 (1) Section 503, Prescription Drug Marketing Act of  
 6-4 1987 (21 U.S.C. Section 353(c)(3)(B));

6-5 (2) the regulations adopted by the secretary to  
 6-6 administer and enforce that Act; or

6-7 (3) the interpretations of that Act set out in the  
 6-8 compliance policy manual of the United States Food and Drug  
 6-9 Administration.

6-10 (a-1) Each [In connection with the returned goods process,  
 6-11 a] wholesale distributor and pharmacy shall administer the process  
 6-12 of drug returns and exchanges to ensure that the process is secure  
 6-13 and does not permit [should establish appropriate business  
 6-14 practices and exercise due diligence designed to prevent] the entry  
 6-15 of adulterated or counterfeit drugs into the distribution channel.

6-16 (e) A manufacturer or wholesale distributor may not accept  
 6-17 payment for, or allow the use of a person's credit to establish an  
 6-18 account for the purchase of, prescription drugs from any person  
 6-19 other than the owner of record, the chief executive officer, or the  
 6-20 chief financial officer listed on the license of a person legally  
 6-21 authorized to receive prescription drugs. Any account for the  
 6-22 purchase of prescription drugs must be established in the name of  
 6-23 the license holder.

6-24 SECTION 10. Section 431.412, Health and Safety Code, is  
 6-25 amended by amending Subsections (a) and (d) and adding Subsection  
 6-26 (b-1) to read as follows:

6-27 (a) A person who is engaged in the wholesale distribution of  
 6-28 a prescription drug, including a repackager but excluding the  
 6-29 original manufacturer [~~and the original labeler of a prescription~~  
 6-30 ~~drug]~~, shall provide a pedigree for each prescription drug that  
 6-31 ~~leaves or at any time has left [is not distributed through]~~ the  
 6-32 normal distribution channel [~~chain]~~ and is sold, traded, or  
 6-33 transferred to any other person.

6-34 (b-1) A retail pharmacy or chain pharmacy warehouse is  
 6-35 required to comply with this section only if the pharmacy or  
 6-36 warehouse engages in the wholesale distribution of a prescription  
 6-37 drug.

6-38 (d) A person who is engaged in the wholesale distribution of  
 6-39 a prescription drug, including a repackager, but excluding the  
 6-40 original manufacturer of the finished form of a prescription drug,  
 6-41 and who is in possession of a pedigree for a prescription drug must  
 6-42 verify before distributing the prescription drug that each  
 6-43 transaction listed on the pedigree has occurred.

6-44 SECTION 11. Section 431.413, Health and Safety Code, is  
 6-45 amended by amending Subsections (a), (c), and (e) and adding  
 6-46 Subsection (e-1) to read as follows:

6-47 (a) A pedigree must include all necessary identifying  
 6-48 information concerning each sale in the product's chain of  
 6-49 distribution from the manufacturer, or from the manufacturer's  
 6-50 third-party logistics provider, co-licensed product partner, or  
 6-51 exclusive distributor, through acquisition and sale by a wholesale  
 6-52 distributor or repackager, until final sale to a pharmacy or other  
 6-53 person dispensing or administering the drug. At a minimum, the  
 6-54 chain of distribution information must include:

6-55 (1) the name, address, telephone number, and, if  
 6-56 available, the e-mail address of each person who owns [~~or~~  
 6-57 ~~possesses]~~ the prescription drug and each wholesale distributor of  
 6-58 the prescription drug [~~, except common carriers and logistics~~  
 6-59 ~~providers];~~

6-60 (2) [~~the signature of each owner of the prescription~~  
 6-61 ~~drug,~~

6-62 [~~3]~~] the name and address of each location from which  
 6-63 the product was shipped, if different from the owner's name and  
 6-64 address;

6-65 (3) [~~4]~~] the transaction dates; and

6-66 (4) [~~5]~~] certification that each recipient has  
 6-67 authenticated the pedigree.

6-68 (c) Each pedigree statement must be:

6-69 (1) maintained by the purchaser and the wholesale

7-1 distributor for at least three years; and

7-2 (2) available for inspection and photocopying not  
 7-3 later than the fifth business day after the date ~~[on]~~ a request is  
 7-4 submitted by the department or a peace officer in this state.

7-5 (e) The department shall:

7-6 (1) conduct a study on the implementation of  
 7-7 electronic pedigrees; and

7-8 (2) in conducting the study under Subdivision (1),  
 7-9 consult with manufacturers, distributors, and pharmacies  
 7-10 responsible for the sale and distribution of prescription drugs in  
 7-11 this state~~[, and~~

7-12 ~~[(3) based on the results of the study, establish an~~  
 7-13 ~~implementation date, which may not be earlier than December 31,~~  
 7-14 ~~2007, for electronic pedigrees].~~

7-15 (e-1) If, after consulting with manufacturers,  
 7-16 distributors, and pharmacies responsible for the sale and  
 7-17 distribution of prescription drugs in this state, the department  
 7-18 determines that electronic track and trace pedigree technology is  
 7-19 universally available across the entire prescription  
 7-20 pharmaceutical supply chain, the department shall establish an  
 7-21 implementation date for electronic pedigree technology. After the  
 7-22 department has established an implementation date, the department  
 7-23 may revise the date. The implementation date may not be earlier  
 7-24 than July 1, 2010.

7-25 SECTION 12. Section 431.414, Health and Safety Code, is  
 7-26 amended by adding Subsection (a-1) to read as follows:

7-27 (a-1) The commissioner of state health services may suspend  
 7-28 or revoke a license if the license holder no longer meets the  
 7-29 qualifications for obtaining a license under Section 431.405.

7-30 SECTION 13. Section 431.415, Health and Safety Code, is  
 7-31 amended by amending Subsection (a) and adding Subsection (a-1) to  
 7-32 read as follows:

7-33 (a) Except as provided by Subsection (a-1), the ~~[The]~~  
 7-34 commissioner of state health services shall issue an order  
 7-35 requiring a person, including a ~~[manufacturer,]~~ distributor~~[,]~~ or  
 7-36 retailer of a prescription drug, to immediately cease distribution  
 7-37 of the drug if the commissioner determines there is a reasonable  
 7-38 probability that:

7-39 (1) a wholesale distributor has:  
 7-40 (A) violated this subchapter;  
 7-41 (B) falsified a pedigree; or  
 7-42 (C) sold, distributed, transferred,  
 7-43 manufactured, repackaged, handled, or held a counterfeit  
 7-44 prescription drug intended for human use that could cause serious  
 7-45 adverse health consequences or death; and

7-46 (2) other procedures would result in unreasonable  
 7-47 delay.

7-48 (a-1) This section does not authorize the commissioner of  
 7-49 state health services to issue a cease and desist order against a  
 7-50 manufacturer.

7-51 SECTION 14. Subchapter N, Chapter 431, Health and Safety  
 7-52 Code, is amended by adding Sections 431.416 and 431.417 to read as  
 7-53 follows:

7-54 Sec. 431.416. PROHIBITED ACTS. (a) The following acts and  
 7-55 the causing of or aiding or abetting of the following acts within  
 7-56 this state are unlawful and prohibited:

7-57 (1) the failure to obtain a license in accordance with  
 7-58 this subchapter;

7-59 (2) operating without a valid license when a license  
 7-60 is required by this subchapter;

7-61 (3) the purchase or receipt of a prescription drug  
 7-62 from a pharmacy in violation of Section 431.411(a) or (a-1);

7-63 (4) if a license is required under Section 431.411(b),  
 7-64 the sale, distribution, or transfer of a prescription drug to a  
 7-65 person who is not authorized under the laws of the jurisdiction in  
 7-66 which the person receives the prescription drug to receive the  
 7-67 prescription drug;

7-68 (5) the failure to deliver a prescription drug to a  
 7-69 specified premise, as required by Section 431.411(c);

8-1 (6) accepting payment or credit for the sale of a  
 8-2 prescription drug in violation of Section 431.411(e);

8-3 (7) the failure to maintain or provide a pedigree as  
 8-4 required by this subchapter;

8-5 (8) the failure to obtain, pass, or authenticate a  
 8-6 pedigree as required by this subchapter;

8-7 (9) providing this state or a representative of this  
 8-8 state or a federal official with a false or fraudulent record  
 8-9 regarding any matter covered under this subchapter;

8-10 (10) making a false or fraudulent statement regarding  
 8-11 any matter covered under this subchapter;

8-12 (11) obtaining or attempting to obtain a prescription  
 8-13 drug by fraud, deceit, or misrepresentation;

8-14 (12) engaging in misrepresentation or fraud in the  
 8-15 distribution of a prescription drug;

8-16 (13) except for a manufacturer's wholesale  
 8-17 distribution of a prescription drug that has been delivered into  
 8-18 commerce pursuant to an application approved under federal law by  
 8-19 the United States Food and Drug Administration, the manufacture,  
 8-20 repacking, sale, transfer, delivery, or holding of, or offering for  
 8-21 sale, any prescription drug that is adulterated, misbranded,  
 8-22 counterfeit, or suspected of being counterfeit or has otherwise  
 8-23 been rendered unfit for distribution;

8-24 (14) except for a manufacturer's wholesale  
 8-25 distribution of a prescription drug that has been delivered into  
 8-26 commerce pursuant to an application approved under federal law by  
 8-27 the United States Food and Drug Administration, the adulteration,  
 8-28 misbranding, or counterfeiting of any prescription drug;

8-29 (15) the receipt of a prescription drug that is  
 8-30 adulterated, misbranded, stolen, obtained by fraud or deceit,  
 8-31 counterfeit, or suspected of being counterfeit, and the delivery or  
 8-32 proffered delivery of such a drug for payment or otherwise; and

8-33 (16) the alteration, mutilation, destruction,  
 8-34 obliteration, or removal of all or any part of the labeling of a  
 8-35 prescription drug or the commission of any other act with respect to  
 8-36 a prescription drug that results in the prescription drug being  
 8-37 misbranded.

8-38 (b) Subsection (a) does not apply to a prescription drug  
 8-39 manufacturer, or an agent of a prescription drug manufacturer, who  
 8-40 is obtaining or attempting to obtain a prescription drug for the  
 8-41 sole purpose of testing the prescription drug for authenticity.

8-42 Sec. 431.417. CRIMINAL PENALTIES. (a) A person commits an  
 8-43 offense if the person engages in the wholesale distribution of  
 8-44 prescription drugs in violation of this subchapter.

8-45 (b) Except as otherwise provided by this section, an offense  
 8-46 under this section is a felony punishable by imprisonment for a term  
 8-47 not to exceed 15 years, a fine not to exceed \$50,000, or both  
 8-48 imprisonment and a fine.

8-49 (c) If it is shown on the trial of an offense under this  
 8-50 section that the person knowingly engaged in the wholesale  
 8-51 distribution of prescription drugs in violation of this subchapter,  
 8-52 the offense is a felony punishable by imprisonment for a term of not  
 8-53 more than 99 years or less than 15 years, a fine not to exceed  
 8-54 \$500,000, or both imprisonment and a fine.

8-55 (d) If conduct constituting an offense under this section  
 8-56 also constitutes an offense under any other law, the actor may be  
 8-57 prosecuted under this section, the other law, or both.

8-58 SECTION 15. Subsections (a-1) and (a-2), Section 431.059,  
 8-59 and Subsections (b) and (c), Section 431.412, Health and Safety  
 8-60 Code, are repealed.

8-61 SECTION 16. The executive commissioner of the Health and  
 8-62 Human Services Commission shall adopt the rules necessary to  
 8-63 implement the changes in law made by this Act not later than  
 8-64 December 1, 2007.

8-65 SECTION 17. The change in law made by this Act applies only  
 8-66 to an offense committed on or after the effective date of this Act.  
 8-67 An offense committed before the effective date of this Act is  
 8-68 covered by the law in effect when the offense was committed, and the  
 8-69 former law is continued in effect for that purpose. For purposes of



9-1 this section, an offense was committed before the effective date of  
9-2 this Act if any element of the offense was committed before that  
9-3 date.

9-4 SECTION 18. This Act takes effect September 1, 2007.

9-5

\* \* \* \* \*